X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Rivaroxaban oral suspension, inhibits free FXa and prothrombinase activity. It has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, it decreases thrombin generation.
Lead Product(s): Rivaroxaban
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Rivaroxaban-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 10, 2023
Details:
Xarelto (rivaroxaban) is an orally bioavailable factor Xa inhibitor and does not require a cofactor (such as Anti-thrombin III) for activity. Activation of factor X to factor Xa via the intrinsic and extrinsic pathways plays a central role in blood coagulation.
Lead Product(s): Rivaroxaban
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Xarelto
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2023
Details:
Xarelto (rivaroxaban) is an orally bioavailable factor Xa inhibitor and does not require a cofactor (such as Anti-thrombin III) for activity. Activation of factor X to factor Xa via the intrinsic and extrinsic pathways plays a central role in blood coagulation.
Lead Product(s): Rivaroxaban
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Xarelto
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2023
Details:
Xarelto (rivaroxaban) is an orally bioavailable factor Xa inhibitor and does not require a cofactor (such as Anti-thrombin III) for activity. Activation of factor X to factor Xa via the intrinsic and extrinsic pathways plays a central role in blood coagulation.
Lead Product(s): Rivaroxaban,Aspirin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Xarelto
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
Rivaroxaban is the most broadly indicated non-vitamin K antagonist oral anticoagulant (NOAC) worldwide and is marketed under the brand name Xarelto. Xarelto is approved for more venous and arterial thromboembolic (VAT) conditions.
Lead Product(s): Rivaroxaban,Aspirin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Xarelto
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2022
Details:
COMPASS open label extension study results support the long-term use of XARELTO (rivaroxaban) plus aspirin for vascular protection in patients with chronic CAD and/or PAD.
Lead Product(s): Rivaroxaban,Aspirin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Xarelto
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2022
Details:
Results from the extension part of the COMPASS study support the long-term use of Xarelto (rivaroxaban) plus aspirin for vascular protection in patients with chronic coronary artery disease (CAD) and/or peripheral artery disease (PAD).
Lead Product(s): Rivaroxaban,Aspirin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Xarelto
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2022
Details:
Previous data demonstrating various benefits of rivaroxaban over VKAs on kidney outcomes, XARENO, non-vitamin K antagonist oral anticoagulant (NOAC) also suggests a potential reduction in kidney failure of Xarelto vs VKA.
Lead Product(s): Rivaroxaban
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Xarelto
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2022
Details:
Data from the two analyses demonstrate the role that the Xarelto® vascular dose plays in PAD patients with and without chronic kidney disease (CKD) and in PAD patients with and without a history of statin therapy.
Lead Product(s): Rivaroxaban,Aspirin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Xarelto
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2022
Details:
The EPO has reversed first instance decision and maintained a Bayer patent (EP1845961) on once-daily administration of rivaroxaban (Xarelto; 10, 15 and 20 mg). The 2.5 mg dose of Xarelto is not affected which is used to prevent blood clots due to certain irregular heartbeat.
Lead Product(s): Rivaroxaban
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Xarelto
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2021
Details:
The study conducted in two parts, Part A evaluated pharmacokinetic (PK) and pharmacodynamic (PD) properties of XARELTO®, and Part B examined the safety and efficacy of XARELTO® compared to aspirin when used for thromboprophylaxis for 12 months.
Lead Product(s): Rivaroxaban
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Xarelto
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2021
Details:
XARELTO® is the only anticoagulant in 20 years to show significant benefit in patients with PAD who remain at high risk for major thrombotic events, including acute limb ischemia and amputation.
Lead Product(s): Rivaroxaban,Aspirin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Xarelto
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2021
Details:
The application is based on evidence from adequate and well-controlled studies of XARELTO® in adults as well as data from two Phase 3 clinical trials of XARELTO® in pediatric populations.
Lead Product(s): Rivaroxaban
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Xarelto
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2021
Details:
The primary results of VOYAGER PAD showed that XARELTO® plus aspirin reduced first events by 15 percent among patients with PAD after LER.
Lead Product(s): Rivaroxaban,Aspirin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Xarelto
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2021
Details:
Rivaroxaban is the first oral Factor Xa Inhibitor approved for paediatric treatment and secondary prevention of VTE. The approval follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency in November 2020.
Lead Product(s): Rivaroxaban
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Xarelto
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2021
Details:
Janssen has submitted a supplemental New Drug Application to the FDA to expand the use of XARELTO® in patients with PAD to include reducing the risk of major thrombotic vascular events in symptomatic patients after recent lower-extremity revascularization.
Lead Product(s): Rivaroxaban
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Xarelto
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
